Inventor
YEE CASSIAN
KR17 patents
⚠️ This page may combine multiple inventors who share the name “YEE CASSIAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV TEXAS
7 patentsUS11696933B2Jul 11, 2023
HLA-restricted VCX/Y peptides and T cell receptors and use thereof
UNIV TEXAS0 citations61
US12173317B2Dec 24, 2024
Use of histone modifiers to reprogram effector T cells
UNIV TEXAS0 citations58
US12552851B2Feb 17, 2026
T cell receptors with VGLL1 specificity and uses thereof
UNIV TEXAS0 citations55
US12319740B2Jun 3, 2025
Methods for production of tissue resident memory-like T cells and use thereof
UNIV TEXAS0 citations52
US11684657B2Jun 27, 2023
HLA-restricted VGLL1 peptides and use thereof in promoting an immune response in a subject
UNIV TEXAS0 citations52
US12202877B2Jan 21, 2025
T cell receptors with mage-B2 specificity and uses thereof
UNIV TEXAS0 citations50
US12178787B2Dec 31, 2024
T cell receptors for immunotherapy
UNIV TEXAS0 citations44
YEE CASSIAN
4 patentsUS9809797B2Nov 7, 2017
Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
YEE CASSIAN5 citations81
US11052140B2Jul 6, 2021
Methods of treatment using conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
YEE CASSIAN0 citations56
US10328135B2Jun 25, 2019
Method of obtaining cytolytic T cells by using mutant tumor epitopes
YEE CASSIAN0 citations46
US9314516B2Apr 19, 2016
Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
YEE CASSIAN0 citations46
HUTCHINSON FRED CANCER RES
2 patentsTHE FRED HUTCHINSON CANCER RES CENTER
2 patentsUS11098284B2Aug 24, 2021
Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
THE FRED HUTCHINSON CANCER RES CENTER1 citations68
US10072246B2Sep 11, 2018
Enhanced generation of cytotoxic T lymphocytes by IL-21 mediated FoxP3 suppression
THE FRED HUTCHINSON CANCER RES CENTER1 citations58